Evidence map›Paper›PMID 31932093›Full record

Trial reportOphthalmology2020

The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study.

Paula Anne Newman-Casey, Leslie M Niziol, Brenda W Gillespie, Nancy K Janz, Paul R Lichter, David C Musch

Open access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 1 pooled it
16.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 1 synthesis or guideline pooled it, 187 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2022
    Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Polypharmacy in glaucoma management: a narrative review.Irish journal of medical science · 2026
    Review
  18. Article
  19. Article
  20. Article

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Paula Anne Newman-CaseyDepartment of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, Michigan. Electronic address: panewman@med.umich.edu.
Leslie M NiziolDepartment of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, Michigan.
Brenda W GillespieDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan.
Nancy K JanzDepartment of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, Michigan.
Paul R LichterDepartment of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, Michigan.
David C MuschDepartment of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, Michigan; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan.
University of Michigan · USMichigan Department of Health and Human Services · US

Funding

Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
Improving glaucoma self-management with technology-supported counselorsK23EY025320 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NEWMAN-CASEY, PAULA ANNE · 2016 to 2019
$920k
Glaucoma progression ? Modeling its trajectory and contributing factors: evidence from AGIS and CIGTSR21EY028997 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MUSCH, DAVID C · 2018 to 2019
$442k
Insights on Glaucoma from Analysis of the CIGTS DataR21EY020912 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MUSCH, DAVID C · 2011 to 2012
$426k
NEI NIH HHS K23 EY025320NEI NIH HHS R21 EY020912NEI NIH HHS R21 EY028997NIDDK NIH HHS P30 DK092926
6 · The paper itself

Abstract

purposeTo evaluate the relationship between medication adherence and visual field progression in participants randomized to the medication arm of the Collaborative Initial Glaucoma Treatment Study (CIGTS).

designThe CIGTS was a randomized, multicenter clinical trial comparing initial treatment with topical medications to trabeculectomy for 607 participants with newly diagnosed glaucoma.

participantsThree hundred seven participants randomized to the medication arm of the CIGTS.

methodsParticipants were followed up at 6-month intervals for up to 10 years. Self-reported medication adherence and visual fields were measured. Medication adherence was assessed by telephone from responses to the question, "Did you happen to miss any dose of your medication yesterday?" The impact of medication adherence on mean deviation (MD) over time was assessed with a linear mixed regression model adjusting for the effects of baseline MD and age, cataract extraction, interactions, and time (through year 8, excluding time after crossover to surgery). Medication adherence was modeled as a cumulative sum of the number of prior visits where a missed dose of medication was reported.

main outcome measureMean deviation over time.

resultsThree hundred seven subjects (306 with adherence data) were randomized to treatment with topical medications and followed up for an average of 7.3 years (standard deviation, 2.3 years). One hundred forty-two subjects (46%) reported never missing a dose of medication over all available follow-up, 112 patients (37%) reported missing medication at up to one third of visits, 31 patients (10%) reported missing medication at one third to two thirds of visits, and 21 patients (7%) reported missing medication at more than two thirds of visits. Worse medication adherence was associated with loss of MD over time (P = 0.005). For subjects who reported never missing a dose of medication, the average predicted MD loss over 8 years was 0.62 dB, consistent with age-related loss (95% confidence interval [CI], 0.17-1.06; P = 0.007); subjects who reported missing medication doses at one third of visits had a loss of 1.42 dB (95% CI, 0.86-1.98; P < 0.0001); and subjects who reported missing medication doses at two thirds of visits showed a loss of 2.23 dB (95% CI, 1.19-3.26; P < 0.0001).

conclusionsThis longitudinal assessment demonstrated a statistically and clinically significant association between medication nonadherence and glaucomatous vision loss.

Indexed as

Drug MonitoringTrabeculectomyAdultAgedAntihypertensive AgentsDisease ProgressionFemaleFollow-Up StudiesGlaucoma, Open-AngleHumansIntraocular PressureMaleMiddle AgedRetrospective StudiesTonometry, OcularVision DisordersAntihypertensive Agents

Identifiers

PMID31932093
PMCPMC7093219
OpenAlexW3000212275

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.